Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next-

generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of

Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to

examine the use of a non-invasive liquid biopsy in early diagnosis of breast cancer. This study was

unique in that the ctDNA analyses was performed before any invasive diagnostic procedure or

treatment.

The SafeSEQ liquid biopsy technology has shown sensitivity down to five mutant molecules in a

background of ten thousand normal ones (or 0.05% mutant allele frequency also known as MAF).

Utilizing the genes TP53 and PIK3CA, which are commonly mutated in breast cancer, investigators

compared the results of traditional standard-of-care tissue biopsy with those of liquid biopsy to

determine the degree to which a highly sensitive assay might complement clinical assessment of

disease. Of the 13 mutations detected in 10 of the primary breast cancer patients (out of a total of 29

samples) 8 mutations had a variant allele frequency less than 0.39%.

Comparing tissue to liquid biopsy, eight patients had detectable mutations in ctDNA with concordant

results between tissue and plasma. Liquid biopsy testing with SafeSEQ detected an additional three

patients with ctDNA mutations that were not present in the tissue. The breast cancer samples with

detected ctDNA biomarkers were significantly associated with a lower patient age, a higher tumor size,

and higher imaging score (indicating higher likelihood of neoplastic disease).

“We have shown in this study how important a sensitive technology is for early detection of breast

cancer, as trace amounts of circulating tumor DNA may be lost by the detection method leading to false-

negative results”, said Dr. Emilio Alba, senior author of the Biomedical Research Institute of Malaga.

“Studies of this kind have not been attempted before due to limitations of the technology, and it is great

to see Sysmex Inostics leading the path forward for early detection.”

The publication “Detection of TP53 and PIK3CA mutations in circulating tumor DNA using Next-

Generation Sequencing in the screening process for early breast cancer diagnosis”, was published online

in the Journal of Clinical Medicine in August of 2019. https://doi.org/10.3390/jcm8081183

 

About Sysmex Inostics

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company that is a pioneer

in blood-based cell-free tumor DNA (ctDNA) mutation detection in oncology utilizing highly sensitive

technologies such as OncoBEAM™ (digital PCR) and SafeSEQ (NGS). These technologies were initially

developed by experts at the Johns Hopkins School of Medicine over a decade ago and this deep

expertise in ctDNA analysis extends to the core of Sysmex Inostics’ capabilities for technology

development and implementation.

With more than 10 years’ of experience in liquid biopsy, Sysmex Inostics is a trusted partner to leading

pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer

therapies to global markets, from discovery through companion diagnostics.

Sysmex Inostics’ OncoBEAM™ and SafeSEQ services are readily available to support clinical trials and

research in oncology. In addition, OncoBEAM™ tests are available through a CLIA certified laboratory for

routine clinical analysis as well as distributed kit products in the EU and Asia Pacific.

Sysmex Inostics’ headquarters and GCP Service Laboratory are located in Hamburg Germany; Sysmex

Inostics’ CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland. For more

information refer to www.sysmex-inostics.com or email info@sysmex-inostics.com.

Contact:

Sysmex Inostics

Press Release

Phone: +49-(0)-40-3259070

Mail: info@sysmex-Inostics.com 

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Cancer-News

2 months
24 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
Melanoma Rates Decline Found in Younger Population
Melanoma Rates Decline Found in Younger Population
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 5 days
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
Category: Acute Lymphoblastic Leukemia
7 Views
Cancer-News 2 weeks
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
Category: Acute Lymphoblastic Leukemia
36 Views
Stan 2 months
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Patient Priorities Should be Paramount when Measuring Quality in Cancer Care According to Panelists at NCCN Policy Summit
Category: Acute Lymphoblastic Leukemia
20 Views
Cancer-News 2 months
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
IASLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8th in Barcelona
Category: Acute Lymphoblastic Leukemia
32 Views
Cancer-News 2 months
IPS based approach for treating virus-induced tumors
IPS based approach for treating virus-induced tumors
Category: Acute Lymphoblastic Leukemia
12 Views
Cancer-News 2 months
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Category: Acute Lymphoblastic Leukemia
48 Views
Cancer-News 2 months
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER  PATIENT GROUP AT WCLC 2019
AMGEN ANNOUNCES NEW CLINICAL DATA EVALUATING NOVEL INVESTIGATIONAL KRASG12C INHIBITOR IN LARGER PATIENT GROUP AT WCLC 2019
Category: Acute Lymphoblastic Leukemia
28 Views
Cancer-News 2 months
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Soricimed and Image Analysis Group Partner to Validate Predictive Imaging Markers for SOR-C13 Treatment Response in Solid Cancer Tumors
Category: Acute Lymphoblastic Leukemia
15 Views
Cancer-News 2 months
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Intraoperative Teamwork of Breast Cancer Surgeon and Pathologist Greatly Reduces Need for Second Surgery After Lumpectomy
Category: Acute Lymphoblastic Leukemia
23 Views
Cancer-News 2 months